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Abstract
Background: Transcriptional responses to small molecules can provide insights into drug mode of action (MOA).
The capacity of the human malaria parasite, Plasmodium falciparum, to respond specifically to transcriptional
perturbations has been unclear based on past approaches. Here, we present the most extensive profiling to date of
the parasite’s transcriptional responsiveness to thirty-one chemically and functionally diverse small molecules.
Methods: We exposed two laboratory strains of the human malaria parasite P. falciparum to brief treatments of
thirty-one chemically and functionally diverse small molecules associated with biological effects across multiple
pathways based on various levels of evidence. We investigated the impact of chemical composition and MOA on
gene expression similarities that arise between perturbations by various compounds. To determine the target
biological pathways for each small molecule, we developed a novel framework for encoding small molecule effects
on a spectra of biological processes or GO functions that are enriched in the differentially expressed genes of a
given small molecule perturbation.
Results: We find that small molecules associated with similar transcriptional responses contain similar chemical
features, and/ or have a shared MOA. The approach also revealed complex relationships between drugs and
biological pathways that are missed by most exisiting approaches. For example, the approach was able to partition
small molecule responses into drug-specific effects versus non-specific effects.
Conclusions: Our work provides a new framework for linking transcriptional responses to drug MOA in P.
falciparum and can be generalized for the same purpose in other organisms.
Background
Malaria continues to take a large toll on the health and
economies of some of the world’s poorest nations. Drugs
remain the primary option for dealing with malaria in-
fection although there are promising clinical trials that
may pave the way for the use of vaccines against the dis-
ease [1]. In spite of enormous progress in the fight
against the disease, the emergence of drug resistance to
artemisinin, the only anti-malarial drug for which clin-
ical resistance is not yet widespread, threatens to re-
verse the gains [2, 3]. There is an urgent need to
fast-track the development of new anti-malarials.
Fortunately, high-throughput and phenotypic screens
have provided several potential drug leads. Through
public and private efforts, nearly six million com-
pounds have been screened leading to the identifica-
tion of thousands of active compounds [4–6]. The
Malaria Box, an open access “pharmacological test
kit” has been made freely available to malaria re-
searchers in an effort to spur antimalarial dug devel-
opment [6]. The malaria drug development pipeline
now contains over a dozen new drugs and several
new combinations of approved drugs are in various
stages of pre-clinical and clinical trials [7]. Approxi-
mately half of these new drugs have unknown mecha-
nisms. An understanding of the mode of action
(MOA) of these compounds would help prioritize and
optimize them while also highlighting potential
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resistance mechanisms. This could help mitigate the
high rate of failure in the drug development pipeline
or rapid emergence of drug resistance. Furthermore,
even compounds with no potential to be developed
into useful therapeutics are valuable as tools for prob-
ing the parasite’s biology [6].
Transcriptional profiling of cells exposed to small mol-
ecules has been successfully demonstrated as useful in
understanding drug MOA especially in human cell lines.
For instance, the Connectivity Map (CMap) [8, 9], a
database of gene expression profiles from cancer cell
lines exposed to multiple drugs of known MOA has
been used to successfully predict the MOA of new drugs
[10, 11]. However, chemical perturbation of P. falcip-
arum, which has been widely described as transcription-
ally hard-wired [12–14], is thought to provoke little in
the way of a specific response. For example, treatment of
the parasite with lethal anti-folate drugs for up to 24 hrs
did not reproducibly induce up-regulation of genes in
the folate pathway or elsewhere in the genome [12]. Ex-
posure to chloroquine (CQ) was reported to have no ef-
fect on the transcript levels of genes presumed to be
involved in its MOA [13, 14]. However, in other studies,
perturbation of the parasite with a polyamine synthesis
inhibitor, diflouromethylornithine- DFMO [15], febrile
temperatures [16], artesunate [17, 18] and an inhibitor
of sphingomyelin synthase [19] were found to provoke
transcriptional changes in the expected target biological
pathways. These reports suggest that the reported lack
of responsiveness to CQ and anti-folate drugs cannot be
generalized to all perturbations. In an earlier large-scale
perturbation of malaria parasites with 20 drugs [20],
59 % of genes responded transcriptionally to at least
one. Some drugs, including CQ, quinine and colcichine
affected fewer than 50 genes, while drugs like apicidin,
trichostatin A and staurosporine affected more than 250
genes and, importantly, even for drugs that only mod-
estly affected gene expression, the effects were highly re-
producible to those in other experiments within the
same study [20]. The ability of the parasite to re-
spond in a reproducible way implies that the response
is physiologically relevant and coordinated. Except for
the study by Hu et al. [20], transcriptional studies in
the parasite have focused on only one drug at a time,
making it difficult to reach general conclusions about
the parasite’s capacity to mount specific transcrip-
tional responses [12, 13, 15]. We expand on these
previous reports to investigate the extent to which
transcriptional responses in P. falciparum can indicate
precise small molecule targets and/or broader bio-
logical effects. To do this, we devised a 6 step ap-
proach that involves: i) performing perturbations with
31 chemically and functionally diverse drugs; ii) min-
imizing biological variation among samples by
leveraging the multiplex exon array developed in our
lab; iii) generating perturbations in two genetically
and phenotypically distinct lab clones; iv) exposing
parasites only briefly (2 hrs) to small molecules to
minimize secondary effects; v) minimizing non-
specific perturbation effects by normalizing transcript
levels relative to all other perturbations rather than to
untreated controls as is typically done, and, vi) lever-
aging multiple independent datasets to cross-validate
that transcriptional responses reflect biologically
meaningful small molecule relationships.
Results
Overview of the study
We compiled a set of 31 chemically and functionally
diverse small molecules associated with inhibition of
biological processes involving a wide range of cellular
compartments: the cell membrane (cerulenin, dl-
threo-1-phenyl-2-palmitoylamino-3-morpholino-1-pro-
panol (PPMP), dideoxyadenosine, fenofibrate), cyto-
plasm (geldanamycin, methotrexate, epoxomicin,
vincristine, 5-fluorouracil), nucleus (methyl methane
sulfonate, olomucine, apicidin, JQ1, curcumin), digest-
ive vacuole (chloroquine, tafenoquine, nelfinavir, E64),
mitochondria (proguanil, atovaquone, z-Val-Asp-fluor-
omethylketone, chloramphenicol, doxycycline, rapamy-
cin) and apicoplast (doxycycline, chloramphenicol,
cerulenin, PPMP). Six compounds (artemisinin and
five novel compounds- SJ194935, SJ119930, SJ140722,
SJ292024 and SJ77572) lacked adequate information
to be associated with any biological process or cellu-
lar compartment. Detailed information for all com-
pounds is provided in Table 1 alongside their
PubChem identification ids (CID) for retrieving their
chemical structures and additional information. The
association between each of the compounds and a
given biological process in P. falciparum is supported
by various levels of evidence extracted from literature
sources and the BRENDA enzyme database [21]. Cri-
teria utilized in selecting the small molecules include
parasite growth inhibition (IC50), enzyme or func-
tional assays, protein structures with co-crystalized
compound in the protein data bank (PDB) and mo-
lecular docking simulations (Table 1).
Synchronized cultures of two laboratory clones, Dd2
and HB3, were exposed for 2 h to each compound at a
single developmental stage (24 h trophozoites) at a con-
centration (IC50) obtained from literature sources or de-
termined by our laboratory (Table 1). Genome-wide
transcript abundances were determined for each drug
perturbation by microarrays.
Previous studies in P. falciparum noted only very sub-
tle transcriptional responses, largely attributed to gener-
alized stress responses [12, 13, 20]. Therefore, we
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Table 1 Summary of small molecule perturbations
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undertook additional data processing steps of RMA-
normalized (see Methods) signal intensity data. First, for
each perturbation, we averaged the signal intensity for
each gene across two distinct lab clones (Dd2 and HB3),
to enhance signal-to-noise ratio as demonstrated in the
CMap project [10, 22]. We further validated that aver-
aging gene expression data across two different strains
in this way strengthens the identification of drug MOA
(see Additional file 1: section D). Importantly, because
the two clones have very different geographical and drug
selection histories, they effectively serve as robustly in-
dependent replicates for each perturbation. Secondly, we
computed a compound-specific response index for each
gene by normalizing the gene’s average transcript level
following perturbations in the two clones against its
average level across all perturbations within the same ex-
perimental batch (Additional file 2) to increase signal-
to-noise ratio [23]. This normalization procedure uses
distinct biological replicates to help mitigate non-
specific transcriptional responses associated with
many perturbations as well as experimental batch ef-
fects. This approach differs significantly from previous
studies [12, 13, 20] in P. falciparum that relied on
normalization using untreated controls for single pertur-
bations; in this case, widespread non-specific transcrip-
tional responses can obscure perturbation-specific
responses (additional evidence in support of this is in
Additional file 1: section D).
Global relationships in small molecule transcriptional
responses relate to chemical structure
To obtain a global view of transcriptional relationships
between small molecules, we computed a correlation be-
tween each pair of compounds using the genome-wide
response index (Fig. 1, Additional file 1 for data). The
genome-wide response index for each compound is the
Fig. 1 Hierarchical clustering of compounds based on their genome-wide response indices for each gene across two parasite samples. The
respond index for each gene in a given perturbation is obtained as the ratio between the average transcript level of the gene following a 2 h
exposure to the compound in two parasite samples and the average transcript level of the same gene across all perturbations performed in the
same batch of experiments. The clustering of the compounds reveals two broad groupings (Class I- red labels and Class II- green labels) in which
compounds within a group are positively correlated to each other but negatively correlated to compounds in a different group
Siwo et al. BMC Genomics  (2015) 16:1030 Page 4 of 17
response index for each gene following exposure to the
compound. All 31 compounds clustered into only two
broad groups (Fig. 1), hereafter referred to as Class I and
II. Class I compounds are generally highly positively cor-
related to compounds within the class but are negatively
correlated to those of Class II. Similarly, Class II com-
pounds tend to be highly positively correlated to each
other but negatively correlated to those in Class I (Fig. 1).
These broad groupings have not been reported before,
possibly because previous studies involved only one or
two drug perturbations and the largest study to date in-
volved 20 drugs [20].
The biological response of cells to small molecules is
dependent on chemical structure. Small molecules with
similar chemical components have similar biological ef-
fects as supported by structure activity relationships
(SAR) studies and correlations between gene expression
effects of drugs and their chemical structures [24–27].
To better understand the role of chemical structure on
the observed dichotomy (Fig. 1), we hierarchically clus-
tered the compounds based on their PubChem substruc-
ture fingerprints (Additional file 1: Figure S1; see
Additional file 3 for the fingerprints). The PubChem sub-
structure fingerprint clusters to some extent recapitulate
the transcription profile clusters (Additional file 1: Figure
S1). In particular, 8 of 9 (89 %) Class I compounds (based
on transcriptional responses) also cluster together
purely based on substructure fingerprints (hypergeo-
metric test P = 0.04, Additional file 1: Figure S1) while
11 out 12 (92 %) Class II compounds are placed in a
separate cluster based on substructure fingerprints
(hypergeometric test P = 0.006, Additional file 1:
Figure S1). Furthermore, we corroborated these obser-
vations using an independent method (multidimen-
sional scaling, MDS) to view the pairwise distances
between the compounds based on their chemical features.
In the 2-dimensional MDS plot (Additional file 1: section
B and Additional file 1: Figure S2), Class II compounds
are enriched in a distinct quadrant of the plot (hypergeo-
metric test P = 0.002, Additional file 1: Figure S2) demon-
strating a strong association between their similarity in
the chemical and transcriptional spaces. That is, small
molecules that are chemically similar are also more likely
to induce similar transcriptional responses.
Fig. 2 Key substructure difference between Class I and II compounds identified using the rule induction algorithm OneR. Two Class I compounds
(chloroquine and apicidin) and two Class II compounds (MMS and cerulenin) are shown as an example. The substructures are numbered from 0 to
880, with the position of a given substructure referred to as its bit position. The bit structure represents a chemical element, group, ring structure
or atom pairs based on the PubChem substructure fingerprints. The presence of a given substructure is encoded by 1 and the absence by a 0.
Class I and II compounds are largely differentiated at bit position 185 which encodes the substructure fingerprint ‘≥2 any ring size 6’
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Next, we investigated whether Class I and II compounds
can be differentiated by the presence/absence of a
particular chemical substructure using an unbiased
approach. Application of the rule induction algorithm
OneR [28, 29]) revealed that the PubChem fingerprint ‘≥2
any ring size 6’ is present in 15 out of 19 (79 %, hypergeo-
metric test P = 0.01) Class I compounds as compared to
only 4 out of 12 (33 %, hypergeometric test P = 0.002)
Class II compounds (Fig. 2). This demonstrates that
this substructure is enriched in Class I compounds
and is associated with gene expression differences
between Class I and Class II compounds.
Drug relationships depend on both chemical structure
and MOA
Correlations between small molecule transcriptional
responses can arise due to two main reasons. First,
small molecules that have similar chemical features
are more likely to induce similar transcriptional
changes [24–27]. However, not all chemically similar
compounds have similar biological effects [30]. Sec-
ondly, small molecules that target the same enzyme
or pathway can induce similar transcriptional changes
even when their structures are unrelated [27]. To de-
termine and quantify whether these two factors are at
play in the observed small molecule relationships
(Fig. 1), we performed principal component analysis
(PCA) on the transcriptional correlations between the
compounds (Fig. 3). We found that 65 % of the vari-
ation in correlations between the compounds is
accounted for by the first dimension of variation. This
dimension splits the compounds into two groups that
are identical to Class I and Class II groups observed
in the heat map (Fig. 1). Because these two com-
pound groups can be largely differentiated using a
single chemical group (Fig. 2), we hypothesize that
chemical features account for a considerable propor-
tion (65 %) of variation in the observed transcrip-
tional responses, consistent with a dominant influence
of chemical structure on functional similarity between
drugs [27]. The aminoquinolones CQ and tafenoquine
(TQ) which target hemoglobin digestion and have re-
lated chemical structures are near each other in the
first two dimensions of the PCA plot (Fig. 3), sup-
porting the hypothesis that the transcriptional re-
sponses capture both chemical similarity and MOA.
However, some small molecules that differ in their
structure have the same MOA. For example, E64 is
chemically distinct from the aminoquinolones (CQ
and TQ) but affects the same pathway (hemoglobin
digestion) as this class of drugs (Fig. 3). In line with
this, E64 is similar to CQ and TQ based on transcriptional
effects (Fig. 3). An exception to this is nelfinavir- another
hemoglobin digestion inhibitor (Fig. 3). Because the
Fig. 3 Principle component analysis (PCA) of transcriptional correlations between the small molecules. The first component of variation
(Dim 1) splits the compounds into two clusters identical to those observed by hierarchical clustering of the compounds (Fig. 1). The
PCA plot reveals complex drug relationships involving both chemical similarity and MOA. Compounds lacking a ring system (PPMP,
olomucine, MMS, cerulenin, epoxomicin and z-Val-Asp) occupy the upper left quadrant of the plot in spite of their distinct MOAs,
supporting a dominant influence of chemical structure on global small molecule relationships. An exception is E64 which occupies a
position on the plot next to other hemoglobin digestion inhibitors (shown in red- CQ, TQ and E64). *Although the MOA of artemisinin
is still unknown, the drug has been shown to require activation by heme released during hemoglobin digestion [56]
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similarity between global transcriptional changes induced
by the compounds does not necessarily indicate shared
MOA but is heavily dependent on their chemical structure
similarities [27], in the next section we develop an ap-
proach for identifying biological pathways that can be dir-
ectly linked to MOA.
Small molecules induce transcriptional responses in
expected target pathways
Although some small molecules exhibit high affinity to-
wards specific protein targets, their biological effects are
rarely limited to a single target and many have multiple
targets [31–34]. Therefore, the effect of small molecules
on biological systems can be represented in terms of
how they affect a spectrum of biological processes - a
profile of molecular effects rather than a single MOA.
We performed biological function enrichment analysis
on the top 100 up- and down-regulated genes for each
small molecule perturbation (for gene lists see
Additional file 4). We then constructed a binary vector
for each perturbation in which each element repre-
sents whether a given biological process is enriched
or not among the top 100 genes (up/down-regulated)
by the small molecule (hypergeometric test P < 0.05;
Fig. 4a and b, Additional file 5). This transformation
allows small molecules’ effects to be analyzed as a bi-
partite network (the small molecule-GO network)
consisting of two kinds of nodes: small molecules and
enriched biological processes (Fig. 4c and Additional
file 6). In this network, a small molecule and a
Fig. 4 Representation of small molecule transcriptional effects as binary fingerprints in which “1” encodes an enrichment of a given biological
process in the top 100 induced genes while a “0” represents lack of enrichment of a given process. a Two examples of partial small molecule-GO
fingerprints for chloroquine and artemisnin. b Visualization of the small molecule–GO fingerprints for the 31 compounds as a heatmap in which
the enrichment of a biological process in top 100 up-regulated genes for each compound is represented in red and the lack of enrichment by
green. c The small molecule-GO fingerprints can be visualized in a bipartite network composed of small molecule nodes and biological process
nodes. A focused view of the up-regulated small molecule-GO relationships between rapamycin and PPMP shows that both compounds are
associated with autophagy but only rapamycin is associated with protein import into nucleus and co-translational protein folding
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biological process are connected by an edge if per-
turbation by that small molecule results in differential
expression of genes involved in the process (hyper-
geometric test P < 0.05). This representation gives a
detailed view of relationships among small molecules
than is attainable with correlations or lists of GO en-
richments (Fig. 4c).
In order to understand whether small molecules can
induce transcriptional responses in their expected target
pathways, we examined connections between each com-
pound and biological processes in the small molecule-
GO networks (Table 2 and Additional file 1: Table S1).
We considered the small molecule GO-networks of up-
regulated and down-regulated biological processes separ-
ately. For 19 of 25 compounds for which an expected
target pathway could be established (see evidence levels
in Table 1), at least one of its connections includes the
target pathway (Additional file 1: Table S1). To evaluate
the statistical significance of this, we asked whether each
biological process was perturbed specifically only by the
small molecule (s) annotated as its inhibitor (Additional
file 1: Table S1). Biological processes affected by many
compounds or that are highly variable across conditions
cannot be reliably associated with their inhibitors, in
contrast to those that are affected by only a few com-
pounds. For example, the GO function ‘DNA strand
elongation involved in DNA replication’ was enriched
only in 5-FU perturbations (100 % specificity, FDR = 0),
its expected inhibitor. Transcriptional responses of 8
compounds (5-FU, cerulenin, z-Val-Asp, curcumin,
MMS, methotrexate, epoxomicin and E64) showed
unique enrichment with their target pathways (100 %
specificity, Table 2); these functions were not associated
with transcriptional responses of any other compounds
annotated as targeting other pathways. 72 % of small
molecules with known MOA were correctly associated
to their targets at a specificity threshold of 80 % (FDR =
20 %). Atovaquone- an inhibitor of the electron trans-
port chain- resulted in down-regulation of the GO cat-
egory ‘respiratory electron transport chain’ but had the
lowest specificity (specificity = 61 %, Additional file 1:
Table S1). This low specificity could be a consequence of
the non-specific responsiveness of this pathway to unre-
lated chemical agents, even though only atovaquone and
Table 2 Summary of small molecule perturbations
*In ‘red arrows’ are biological processes enriched in the top 100 up-regulated genes while in ‘blue arrows’ are down-regulated biological processes
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proguanil were expected to directly affect this pathway.
The role of mitochondria in sensing stress and acting as
a gateway to cell death or survival under various pertur-
bations may also account for this [35, 36]. We provide
the specificity of each small molecule association to its
expected target pathway in Additional file 1: Table S1 to
allow a contextual assessment of the false positive rate
for each prediction in this study.
The small molecule-GO networks predict complex
relationships between drugs and biological pathways
Unlike previous work on drug-drug networks in other
species [10], the small molecule-GO network provides
hypotheses for why two drugs are biologically related.
For example, the small molecule-GO network confirms
that the drugs CQ, TQ and E64 are related through the
GO process ‘proteolysis involved in cellular catabolic
processes’, consistent with the effect of these drugs on
hemoglobin catabolism. In contrast, curcumin and apici-
din- drugs that interfere with regulation of gene expres-
sion through inhibition of histone acetylation and
deactylation, respectively- are both connected to the bio-
logical process ‘regulation of gene expression’ while the
drugs methotrexate and 5-FU which interfere with pyr-
imidine synthesis are connected to the function ‘nucleo-
base-containing compound metabolic process’. The
connection between 5-FU and this biological function is
unexpected in P. falciparum because the parasite lacks a
pyrimidine salvage pathway which is required for the ac-
tivation of 5-FU to an inhibitor of thymidylate synthase
(TS) [37]. Nevertheless, 5-FU is a weak competitive in-
hibitor of the P. falciparum orotate phosphoribosyl
transferase (pfOPRT), an essential step in pyrimidine
biosynthesis [38]. Inhibition of pfOPRT could impact the
synthesis of pyrimidines and provide a connection be-
tween methotrexate and 5-FU activity. To validate the
connection between these two drugs, we measured dose
responses to 5-FU across the Dd2 ×HB3 genetic cross
(Additional file 7) and explored potential genetic deter-
minants of its effects through QTL. A direct apriori test
of the genetic locus containing the pfOPRT gene
(chromosome 5, cM 31.5) shows that parental alleles in
this locus are significantly associated with 5-FU dose re-
sponse with a higher IC50 for progeny inheriting this
locus from the Dd2 parent (LOD = 1.90, P = 0.002). A
genome-wide QTL scan demonstrates that in addition
to this locus, dose response variation to the drug is asso-
ciated with 3 other loci on chromosomes 8 (cM 91.8,
LOD = 2.98), 11 (cM 143.2, LOD = 2.3) and 14 (cM
189.4, LOD = 1.80). The chromosome 8 QTL region in-
cludes the Rad54 gene (PF3D7_0803400) encoding a
DNA repair protein, providing additional support for
the connection between 5-FU and the GO function
‘nucleobase-containing metabolic process’. Thus, the
small molecule-GO network provides a framework for
identifying drug similarities while at the same time
identifying the biological processes underlying the
similarities.
The network approach reveals that while some bio-
logical processes are widely perturbed or affected by
many small molecules, others are only perturbed by only
one or a few small molecules (Fig. 4c). For example, the
biological categories ‘translocation of peptides into host’
(GO:0042000), ‘respiratory electron transport chain’
(GO:0022904) and ‘antigenic variation’ (GO:0020033)
were up-regulated by many compounds (13, 12 and 10,
respectively). These processes may reflect generalized
stress responses that are associated with subsets of small
molecules. In contrast, categories that are up-regulated by
only one small molecule include: ‘protein import into nu-
cleus’ (GO:0000059)- perturbed by rapamycin, ‘N-terminal
protein amino acid acetylation’ (GO:0006474)- per-
turbed by MMS and ‘transposition’ (GO:0032196)-
perturbed by 5-FU.
Transcriptional insights into artemisinin’s MOA
The results above show that transcriptional responses
can be used to predict drug MOA and provide insights
into broad biological effects. The MOA of many anti-
malarial drugs and investigational compounds is cur-
rently unknown. Artemisinin, the front line antimalarial,
has been proposed to act through the generation of free
radicals leading to oxidative stress and damage of pro-
teins [39]. However, the drug also has been associated,
controversially, with direct binding to the SERCA-type
Ca2+ ATPase protein (pfATP6) [40–43] and the Ca2+
binding translationally controlled tumor protein (TCTP)
[44–48]. To mine our data for insights into artemisinin
targets, we examined the small molecule-GO networks
for connections involving artemisinin (Fig. 5). At 100 %
specificity, the up-regulated GO connections to artemisi-
nin are: ‘adhesion to host’ (GO:0044406), ‘glycerol meta-
bolic process’ (GO:0006071), ‘cell cycle’ (GO:0007049),
‘translation’ (GO:0006412) and ‘pyridoxine biosynthetic
process’ (GO:0008615). Recently, Mok et al. [49] identi-
fied processes in the ‘translation’ and ‘regulation of cell
cycle’ GO categories as being up-regulated in parasites
from Southeast Asia that have increased artemisinin
clearance half-life. Furthermore, these processes were
up-regulated in parasite isolates containing genetic vari-
ants associated with artemisinin resistance in the K13
gene. The reported association between artemisinin and
TCTP [44–48] as well as with quiescence [50–52], is
consistent with the enrichment of cell cycle function.
TCTP in other organisms is involved in a variety of pro-
cesses including response to stress, cell cycle, apoptosis
and calcium ion binding [53–55]. In P. falciparum, the
protein binds Ca2+ [45] and artemisinin [44, 46, 48].
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This binding is increased in the presence of heme [48],
consistent with the reported dependence between arte-
misinin activity and hemoglobin digestion [56]. The
down-regulated GO connections to artemisinin at
100 % specificity are ‘endocytosis’ (GO:0006897), ‘cyto-
kinesis’ (GO:0000910), ‘cholesterol metabolic process’
(GO:0008203) and ‘lipid transport’ (GO:0006869). The
connection between the drug and lipid metabolism
has been previously suggested [57–59] and implicated
in resistance to the drug [49]. Thus, artemisinin po-
tentially targets the cell cycle and lipid metabolism.
Predicting MOA of novel compounds by integration
of QTL
Public and private screening efforts have recently led to
the identification of thousands of compounds with cyto-
toxic activity in P. falciparum [4, 5]. Techniques for pre-
dicting MOA of these compounds will be valuable for
their characterization and prioritization for further de-
velopment [60]. Among the compounds profiled in our
study, five (SJ194935, SJ119930, SJ140722, SJ292024 and
SJ77572) were derived from a high-throughput screening
effort by the St Jude’s children’s hospital [5]. To ascertain
the biological effects of these compounds, we deter-
mined the coherence of biological functions predicted
from transcriptional perturbations with those encoded in
QTL associated with dose response variation to the
compounds. The small molecule-GO network demon-
strates that a single compound can perturb more than
one biological process. However, some functions are
perturbed by a single or just a few compounds and
yield predictions of higher specificity. Therefore, we
prioritized the links between these compounds and
each biological function by considering the specificity
of each function.
Out of 13 biological processes connected to SJ194935
in the up-regulated small molecule-GO network, five
(‘cell redox homeostasis’, ‘protein oligomerization’, ‘tRNA
splicing’, ‘heme catabolic process’ and ‘regulation of DNA
replication’) were unique to the compound. Two GO
functions (‘regulation of translation’ and ‘regulation of
RNA stability’) were uniquely connected to this com-
pound in the down-regulated small molecule-GO net-
work. These functions were evaluated for overlaps with
QTL. SJ194935 dose response was associated with a gen-
etic locus on chromosome 14 (cM 106.1, LOD= 3.12). We
searched this locus for genes encoding biological pro-
cesses uniquely (100 % specificity) connected to the com-
pound in the small molecule-GO network. A biological
process shared by these two approaches is ‘cell redox
homeostasis’, a function that involves cytochrome genes,
one of which is present in the QTL (PF3D7_1435000-
cytochrome c oxidase assembly protein, putative; chromo-
some 14 cM 106.1, Table 3).
Similarly, to predict potential MOA of the other
novel compounds, we compared the functional coher-
ence between their unique connections in the small
molecule-GO network and the functions of genes
Fig. 5 Representation of small molecule-GO network for artemisinin. GO biological processes enriched in the top 100 up-regulated genes are
shown as red nodes and down-regulated genes are shown as green nodes.
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located within their QTL. For each small molecule we
considered QTL peaks with at least a LOD score of 2
(Table 3; see Additional file 7 for dose responses used
in QTL). The St Jude compound SJ119930 had no
unique biological process connections in the up-/
down-regulated small molecule-GO networks; hence
predictions could not be made at 100 % specificity.
Two functions were predicted as its targets at 94 %
specificity in the up-regulated network: ‘respiratory
complex IV assembly’ and ‘autophagic vacuole assem-
bly’. QTL mapping revealed a suggestive peak on
chromosome 8 (cM 83.2) but we could not identify
genes whose functions are coherent to those pre-
dicted in the network. For SJ140722, a single bio-
logical process (‘dolichol biosynthetic process’) was
uniquely connected to it in the up-regulated network
and no unique connections were observed in the
down-regulated network. We did not find any gene
with this function in the QTL region associated with
variation in dose response to the compound. Another
compound, SJ292024, was uniquely connected to the
biological process ‘ribosomal large subunit biogenesis’
in the up-regulated network. Nine processes were
connected to this compound at 100 % specificity in
the down-regulated network: ‘protein glycosylation’,
‘respiratory chain IV complex assembly’, ‘intein medi-
ated protein splicing’, ‘drug transmembrane transport’,
‘phosphorylation’, ‘catabolic process’, ‘DNA strand
elongation involved in DNA replication’, ‘signal peptide
processing’ and ‘terpenoid biosynthetic pathway’. The
QTL peak associated with this compound (chromo-
some 5, cM 65.9) includes the gene encoding the
multi-drug resistance tansporter, pfMDR1 coherent
with prediction connection between the drug and the
GO function ‘drug transmembrane transport’.
Discussion
Drug responses are complex: perturbation of a single
protein can lead to direct effects on its multiple func-
tions and indirect effects can be perpetuated through
the cellular network. In addition, broad chemical
properties of compounds, for example hydrophobicity,
can affect multiple biological processes. Therefore,
understanding the nature of transcriptional responses
to specific perturbations and filtering non-specific ef-
fects requires knowledge of how cells respond to a
range of chemical perturbations. Without this know-
ledge, it may not be possible to identify transcrip-
tional responses specifically induced by a perturbation
vs. those resulting from general stress. This may be
one reason that the parasite’s transcriptional re-
sponses to perturbations have been considered to be
non-specific [12, 13]. Our study design utilizes many
small molecule perturbations in the same experiment
and provides a novel way to disentangle transcrip-
tional responses.
The results presented in this work demonstrate that
transcriptional responses can point to drug MOA in P.
falciparum. The observation that small molecules con-
taining similar chemical substructures also tend to show
similar transcriptional responses (Fig. 2 and Additional
file 1: Figure S1) imply that these responses are specific
to the perturbations. The clustering of the 31 small mol-
ecules into two broad classes (Fig. 1) coupled with the
observation that a single chemical substructure (Fig. 2)
can distinguish these classes implies that a large compo-
nent of transcriptional responses are due to specific
chemical features, most prominently rings (Fig. 2 and
Additional file 1: Figure S2). Even though this study has
profiled the largest set of small molecule transcriptional
responses in P. falciparum to date, it is important to
note that the 31 small molecules represent a small pro-
portion of chemical diversity. Our study provides a foun-
dation for more extensive studies in future.
To capture the complexity of small molecule relation-
ships, we developed a novel framework for encoding
small molecule effects into binary fingerprints of bio-
logical categories that are enriched in their perturbed
gene sets (Fig. 4a, b and c). We have demonstrated that
this representation allows a detailed view of complex re-
lationships that can exist between small molecules in
which some biological functions are affected by multiple
compounds while others are specifically affected by a
smaller number of compounds (Fig. 4c). The resulting
small molecule-GO network has enabled us to tease
apart small molecule-specific effects from non-specific
responses, thereby providing a reliable approach for
predicting small molecule MOA (Table 2 and Additional
file 1: Table S1). From this network, each small molecule
can be queried to determine the biological processes that
are uniquely connected to it as well as those that it
shares with one or more other compounds (Fig. 4c). This
approach can be applied in predicting drug MOA, un-
derstanding cross-resistance between drugs, drug-drug
interactions and off-target effects.
We observed that some small molecules perturb a
wide array of functions, while others have a specific tar-
get pathway. Small molecules have to cross at least one
Table 3 Prediction of MOA of novel compounds from St Jude
using QTL and small molecule-GO network
Small molecule QTL peaks LOD Coherent functions in QTL and
unique connections in network
SJ194935 14 cM 106.1 3.12 Cell redox
SJ119930 8 cM 83.2 2.18 None
SJ140722 7 cM 66.1 2.71 None
SJ292024 5 cM 65.9 2.23 Drug transmembrane transport
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membrane to reach their expected target. Broad chem-
ical properties of small molecules such as their hydro-
phobicity, molecular weight, solubility and pKa could
indirectly interfere with multiple biological processes.
Once a small molecule reaches its target, the direct in-
hibition of a target enzyme, for example, can result in
metabolic changes that stimulate downstream biological
processes. Furthermore, drugs that bind to distinct mo-
lecular targets within the same pathway can lead to simi-
lar biological effects. It is important to identify all these
levels at which a drug can have a biological effect be-
cause the therapeutic success of a drug is determined by
factors such as drug transport, metabolism and resist-
ance that in many cases are distinct from molecular
targets of the drug. Most approaches for the predic-
tion of drug MOA in P. falciparum rely on the iden-
tification of single targets [60]. Understanding the full
spectrum of effects of a small molecule could aid in
minimizing off-target effects and enhance the design
of highly specific drugs.
Our study uncovers some potential challenges of
using transcriptional perturbations for predicting drug
MOA and reveals limitations that will need to be ad-
dressed in future studies. First, a large library of per-
turbations is needed in order to filter non-specific
effects of small molecules. Secondly, predicting the
MOA of small molecules that target biological pro-
cesses that are non-specifically associated with numer-
ous perturbations will pose a bigger challenge than
those of small molecules that affect pathways that re-
spond to only very few compounds. For example, the
biological process “respiratory electron transport
chain” was connected to 12 compounds in the small
molecule-GO network, increasing the FDR for pre-
dicting the MOA of compounds affecting this process.
However, as more compounds are profiled, the FDR
for such compounds could be reduced. The small
molecule-GO network provides a way to identify
these non-specific effects and is generalizable for the
prediction of drug MOA in other organisms.
Conclusions
We have shown the utility of transcriptional perturba-
tions in predicting drug MOA and provide novel bio-
logical insights. Similarities between transcriptional
responses of small molecules depend on their chemical
composition and MOA. In particular, small molecules
containing similar chemical constituents induce similar
transcriptional responses. Furthermore, we determine
that the presence/absence of rings in a compound dom-
inate transcriptional similarities between compounds.
We further show that small molecules with the same
MOA induce similar transcriptional responses. Using a
novel network representation (the ‘small molecule-GO
network’), we demonstrate that some biological pro-
cesses are affected by many compounds, potentially
reflecting generalized stress responses, while others are
affected by only one or few compounds. This network
approach provides a hypothesis-testing framework for
explaining similarities between any two or more small
molecules based on the biological processes to which
they are connected in the network. The small molecule-
GO network correctly identifies the MOA of 72 % of
compounds at a specificity of 80 %, establishing that this
approach can be applied for predicting MOA. The
representation of transcriptional responses as a small
molecule-GO network is a novel approach that can be
generalizable to other organisms.
Methods
Parasite cultures
Parasite clones Dd2 and HB3 were cultured using stand-
ard methods in human red blood cells (Indiana Regional
Blood Center, Indianapolis, Indiana) suspended in
complete medium (CM) containing RPMI 1640 with L-
glutamine (Invitrogen Corp.), 50 mg/L hypoxanthine
(Sigma-Aldrich), 25 mM HEPES (Cal Biochem), 0.5 %
Albumax II (Invitrogen Corp.), 10 mg/L gentamicin
(Invitrogen Corp.) and 0.225 % NaHCO3 (Biosource) at
5 % hematocrit. Cultures were grown separately in
sealed flasks at 37 °C under an atmosphere of 5 % CO2,
5 % O2, and 90 % N2. Small molecules were purchased
from Sigma-Aldrich with the exception of JQ1 (provided
by Dr. James Bradner, Harvard Medical School) and the
compounds SJ194935, SJ119930, SJ77572, SJ292024 and
SJ140722 (provided by Dr. Kiplin Guy, St Jude’s Children’s
hospital). Sorbitol double-synchronized cultures of the
two clones were exposed briefly for 2 h to each compound
at a single developmental stage (24 h trophozoites) at a
concentration (IC50) obtained from literature sources or
determined by our laboratory (Table 1).
RNA extraction and cDNA synthesis
Total RNA was extracted from 20mls of culture using
TriZol reagent (Invitrogen, Carlsbad, CA) as described
previously [61]. Quantity of RNA and protein/organic
contamination were determined using Nanodrop (Nano-
Drop Technologies). 300 ng of RNA was used as starting
material for cDNA synthesis using the Sigma WTA2
whole transcriptome amplification kit (Sigma Aldrich, St
Louis, MO). The cDNA synthesis reaction was per-
formed in two steps: library synthesis and library ampli-
fication. To synthesize the cDNA library, 300 ng of
sample RNA was incubated with reverse transcriptase
and non-self-complimentary primers that contain a
quasi-random 3’ end and a universal 5’ end. Primer ex-
tension was then performed using WTA2 polymerase to
generate an OmniPlex cDNA library consisting of
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random, overlapping 100 to 1000 base fragments flanked
by a universal end sequence. Amplification was then per-
formed using primers targeting the universal 5’ ends.
cDNA cleanup was performed using 3 M sodium acetate
and ethanol.
1 μg of cDNA was labeled with Cy3 dye using 65 %
AT rich pre-labeled random hexamers as primers for
cDNA synthesis by Klenow fragment of DNA poly-
merase I. All samples were hybridized to a custom
Nimblegen 12-plex microarray containing 128,179
probes, approximately 22 probes per annotated gene
(PlasmoDB v6.3) with an average of 5 probes per exon
(see Additional file 1: section C and Additional file 1:
Figure S3 for microarray validation information). Hybrid-
izations were performed for 22 h followed by washing of
the arrays as described according to standard protocols
(Roche NimbleGen Inc., Madison, WI). The microarray
image was obtained using a 2uM scanner and probe inten-
sity values extracted using NimbleScan software (Roche
NimbleGen Inc., Madison, WI).
Microarray data processing
Probe intensities were normalized using robust multi-
chip average (RMA) method [62]. This normalization
was performed across all samples hybridized on a single
chip. Transcript level for each gene was obtained by
averaging the processed signal intensity of all the probes
across its exons as follows. Exon signal intensity for each
gene was obtained by averaging the intensities of all
probes within each exon. To determine a significance
threshold for exon expression levels, a background dis-
tribution of signal intensities from a set of 10,000 nega-
tive control probes with no sequence matches to the P.
falciparum genome was generated. A threshold corre-
sponding to the 95th percentile (5 % FDR) of the signal
distribution of the negative control probes was then ap-
plied [63]. To determine gene expression levels, exons
that passed the 5 % significance threshold were sub-
jected to an additional threshold derived from intensities
of 1000 simulated exons each consisting of 20 randomly
sampled negative control probes. Intensities of exons
that passed a 5 % FDR threshold based on this back-
ground distribution were averaged to obtain an average
transcript level for each gene.
Analysis of pairwise relationships between compounds
using genome-wide response profiles
For each perturbation, we averaged the signal intensity
for each gene across two lab clones (Dd2 and HB3). The
resulting data was then used to obtain a compound-
specific response index for each gene by normalizing the
gene’s average transcript level following perturbations in
the two clones against its average level across all pertur-
bations within the same experimental batch to obtain a
gene specific response index. The global transcriptional
response to a small molecule was then represented as a
vector where each element represents a gene specific
response index. This vector is referred to as the
genome-wide response index. Small molecule global
transcriptional relationships were determined using
Pearson correlations between their genome-wide re-
sponse indices. Clustering and visualization of the cor-
relation matrix was performed in R. To determine the
components of variation in the global correlations be-
tween small molecule responses, PCA was performed in
R using the PCA function in the package FactoMineR.
Analysis of small molecule relationships based on
chemical fingerprints
Small molecule relationships in the chemical space were
determined by first converting each small molecule into
a binary fingerprint of 881 elements using the PubChem
2-dimensional substructure fingerprints [64]. Each pos-
ition in the binary fingerprint encodes the presence/ab-
sence of a substructure such as a specific chemical
element, a type of ring system, atom pairing, or atom en-
vironment, etc. A full description of the fingerprints can
be found at [65].
We downloaded chemical structure files (SDF) for
each small molecule from PubChem. Transformation of
chemical structures into substructure fingerprints was
performed in the R statistical package ChemmineR [66].
Small molecule relationships based on the fingerprints
were then visualized by hierarchical clustering. To deter-
mine whether chemical structure accounts for the ob-
served major clustering of small molecules into two
main clusters (named Class I and Class II), small mole-
cules were projected onto a two-dimensional surface
using multidimensional scaling (MDS) in the MASS
package [67] of the R statistical software. Chemical sub-
structures that discriminate Class I from Class II com-
pounds were identified using a rule induction algorithm
(OneR) in the WEKA machine learning package [28].
The OneR algorithm produces a single ‘If-Then’ rule
that identifies a single predictor variable that differenti-
ates between two outcomes [29]. The ability of the rule
to discriminate Class I and II compounds was evaluated
by testing the enrichment of Class I and II molecules
when the rule is applied to the substructure fingerprints
of all the small molecules. The enrichment P-values
were obtained by hypergeometric tests.
Encoding small molecule effects into binary biological
process fingerprints
GO enrichment analysis was performed on the most
responsive genes in the transcriptome (the top 100
[~2 %] most up- and down-regulated genes) and
enriched biological processes (hypergeometric test
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FDR corrected P < 0.05) were determined using the
online platform MADIBA [68]. For each small molecule,
we then represented the transcriptional response as a
binary vector whose elements are biological process cat-
egories that have a value of 1 (when the process is
enriched following the perturbation) and 0 (when the
process is not enriched).
Construction of small molecule-GO networks
To determine the relationships between small mole-
cules to specific biological processes, we constructed
small molecule-GO bipartite networks in which nodes
were either small molecules or biological processes.
Small molecules were connected by an edge to a bio-
logical process if perturbations by the small molecule
were associated with an enrichment (hypregeometric
test P < 0.05) of the biological process in the most re-
sponsive genes to the perturbation (top 100 up- and
down-regulated genes).
Analysis of the effect of small molecules on their
expected target pathways
The effect of small molecules on their expected tar-
get pathways was determined by querying the small
molecule-GO network in the network visualization
software Cytoscape [69]. The expected target path-
way for each small molecule was determined from
literature and the enzyme database BRENDA. For
each small molecule, we determined whether the
biological processes it is connected to in the small
molecule-GO network includes its expected target
pathway. An estimate of the FDR for the association
between a small molecule and its expected biological
pathway was computed as the proportion of small
molecules that were also connected to that category
in the network. A small molecule was regarded as
specifically connected to its expected target pathway
if the FDR was less or equal than 10 %.
Dose response assays and QTL
We performed standard dose response assays across
the Dd2 × HB3 recombinant clones cultured under
varying concentrations of the drugs 5-FU, methotrex-
ate, SJ194935, SJ119930, SJ140722 and SJ292024. Dose
response assays were performed as previously de-
scribed [70] using 4 to 6 replicates of parasite cul-
tures of 37 recombinant clones of the Dd2 × HB3
genetic cross, including the parental lines. Quantita-
tive trait locus (QTL) analysis for the dose responses
was performed using previously published statistical
methods in Pseudomarker v 2.04 [71] and the Dd2 ×
HB3 genetic cross microsatellite linkage maps. The
statistical significance of the obtained log odds scores
(LOD) were obtained from a chi-square distribution,
P = 1 - chi2cdf (2 × LOD score × Log10, degree of free-
dom = 1) where chi2cdf is the Matlab chi-square cu-
mulative distribution function. Gene candidates were
considered as those lying within the region bounded
by the physical location of the genetic marker re-
ported with the highest LOD score and the nearest
markers in the region.
Prediction of MOA of novel compounds
The MOAs of five novel compounds (SJ194935,
SJ119930, SJ140722, SJ292024 and SJ77572) emerging
from a recent phenotypic screen [5] were predicted
by combining predictions from the small molecule
GO network and QTL analysis. To predict MOA
from the small molecule-GO network, the network
was queried in Cytoscape [69] and biological process
connections that are uniquely connected to a given
small molecule of interest selected as potential tar-
gets. Separately, dose response assays were deter-
mined for each of the compounds in 37 parasite
lines in the Dd2 × HB3 genetic cross followed by
QTL analysis. Gene candidates for each small mol-
ecule at a given QTL locus was then determined as
genes located upstream and downstream of the re-
gion lying between the physical location of the QTL
marker and the nearest marker.
The gene candidates at the QTL for a given novel
compound were then examined for any functions that
are related to those predicted as uniquely connected
to the compound in the small molecule-GO network.
The functions shared between the candidate genes
from QTL and those from the small molecule-GO
network were then regarded as potential targets of
the compound.
For arteminsin, the functions shared between its
unique biological process connections in the small
molecule-GO network and previous reports were con-
sidered as its MOA [50–52].
Availability of supporting data
The raw data set supporting the results of this article is
available in the NCBI Gene Expression Omnibus reposi-
tory, [GEO:GSE67127, http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE67127]. The processed data sets
supporting the results of this article are included within
the article (and its additional file (s)).
Additional files
Additional file 1: Supplementary text and figures. (DOCX 441 kb)
Additional file 2: Gene Expression Data. (XLSX 6956 kb)
Additional file 3: PubChem Fingerprints. (XLSX 98 kb)
Siwo et al. BMC Genomics  (2015) 16:1030 Page 14 of 17
Additional file 4: Top 100 and Bottom 100 gene lists for each drug
perturbation. (XLSX 487 kb)
Additional file 5: Drug GO-Matrix. (XLSX 58 kb)
Additional file 6: Small Molecule GO-networks. (XLSX 30 kb)
Additional file 7: Dose Response Profiling. (XLSX 15 kb)
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
GHS and MTF conceived the study. RS, GHS and KBS performed drug and
small molecule perturbation experiments. LAC performed dose response
assays and QTL analysis. GHS, AT, KBS and MTF performed data analysis.
GHS developed and deployed computational methods. GHS and MTF wrote
the paper. All authors have read and approved the paper.
Acknowledgements
GS was supported by an Eck Institute for Global Health Fellowship. This work
was supported by NIH grants AI105657 to MTF. The Dana-Farber Cancer
Institute provided the experimental compound JQ1 and Dr. Kiplin Guy at
Saint Jude’s children’s hospital provided the SJ series of experimental
compounds. We would like to thank Lindsey B. Turnbull for help with data
annotation and curation.
Author details
1Eck Institute for Global Health, Department of Biological Sciences, University
of Notre Dame, Notre Dame, IN 46556, USA. 2Current Address: IBM TJ
Watson Research Center, Yorktown Heights, NY 10598, USA. 3Current
Address: IBM Research-Africa, South Africa Lab, Sandton, Johannesburg 2196,
South Africa. 4Current Address: Memorial Sloan Kettering Cancer Center, New
York, NY 10065, USA. 5Epicenter, Madison, WI 53719, USA.
Received: 11 March 2015 Accepted: 29 October 2015
References
1. RTS SCTP. Efficacy and safety of RTS, S/AS01 malaria vaccine with or without
a booster dose in infants and children in Africa: final results of a phase 3,
individually randomised, controlled trial. The Lancet. 2015;386:4–10.
2. Dondorp AM, Yeung S, White L, Nguon C, Day NP, Socheat D, et al.
Artemisinin resistance: current status and scenarios for containment. Nat
Rev Microbiol. 2010;8(4):272–80.
3. Dondorp AM, Fairhurst RM, Slutsker L, Macarthur JR, Breman JG, Guerin PJ,
et al. The threat of artemisinin-resistant malaria. N Engl J Med.
2011;365(12):1073–5.
4. Gamo FJ, Sanz LM, Vidal J, de Cozar C, Alvarez E, Lavandera JL, et al.
Thousands of chemical starting points for antimalarial lead identification.
Nature. 2010;465(7296):305–10.
5. Guiguemde WA, Shelat AA, Bouck D, Duffy S, Crowther GJ, Davis PH, et al.
Chemical genetics of Plasmodium falciparum. Nature. 2010;465(7296):311–5.
6. Spangenberg T, Burrows JN, Kowalczyk P, McDonald S, Wells TN, Willis P.
The open access malaria box: a drug discovery catalyst for neglected
diseases. PLoS One. 2013;8(6):e62906.
7. Wells TN, van Huijsduijnen RH, Van Voorhis WC. Malaria medicines: a glass
half full? Nature Reviews Drug Discovery. 2015;8:424–42.
8. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, et al. The
Connectivity Map: using gene-expression signatures to connect small
molecules, genes, and disease. Science. 2006;313(5795):1929–35.
9. Lamb J. The Connectivity Map: a new tool for biomedical research. Nat Rev
Cancer. 2007;7(1):54–60.
10. Iorio F, Bosotti R, Scacheri E, Belcastro V, Mithbaokar P, Ferriero R, et al.
Discovery of drug mode of action and drug repositioning from
transcriptional responses. Proc Natl Acad Sci U S A. 2010;107(33):14621–6.
11. Iorio F, Isacchi A, di Bernardo D, Brunetti-Pierri N. Identification of small
molecules enhancing autophagic function from drug network analysis.
Autophagy. 2010;6(8):1204–5.
12. Ganesan K, Ponmee N, Jiang L, Fowble JW, White J, Kamchonwongpaisan S,
et al. A genetically hard-wired metabolic transcriptome in Plasmodium
falciparum fails to mount protective responses to lethal antifolates. PLoS
Pathog. 2008;4(11):e1000214.
13. Gunasekera AM, Myrick A, Le Roch K, Winzeler E, Wirth DF. Plasmodium
falciparum: genome wide perturbations in transcript profiles among mixed
stage cultures after chloroquine treatment. Exp Parasitol. 2007;117(1):87–92.
14. Kritsiriwuthinan K, Chaotheing S, Shaw PJ, Wongsombat C,
Chavalitshewinkoon-Petmitr P, Kamchonwongpaisan S. Global gene
expression profiling of Plasmodium falciparum in response to the anti-
malarial drug pyronaridine. Malar J. 2011;10:242.
15. van Brummelen AC, Olszewski KL, Wilinski D, Llinas M, Louw AI, Birkholtz
LM. Co-inhibition of Plasmodium falciparum S-adenosylmethionine
decarboxylase/ornithine decarboxylase reveals perturbation-specific
compensatory mechanisms by transcriptome, proteome, and metabolome
analyses. J Biol Chem. 2009;284(7):4635–46.
16. Oakley MS, Kumar S, Anantharaman V, Zheng H, Mahajan B, Haynes JD,
et al. Molecular factors and biochemical pathways induced by febrile
temperature in intraerythrocytic Plasmodium falciparum parasites. Infect
Immun. 2007;75(4):2012–25.
17. Natalang O, Bischoff E, Deplaine G, Proux C, Dillies MA, Sismeiro O, et al.
Dynamic RNA profiling in Plasmodium falciparum synchronized blood
stages exposed to lethal doses of artesunate. BMC Genomics. 2008;9:388.
18. Mok S, Imwong M, Mackinnon MJ, Sim J, Ramadoss R, Yi P, et al. Artemisinin
resistance in Plasmodium falciparum is associated with an altered temporal
pattern of transcription. BMC Genomics. 2011;12:391.
19. Tamez PA, Bhattacharjee S, van Ooij C, Hiller NL, Llinas M, Balu B, et al. An
erythrocyte vesicle protein exported by the malaria parasite promotes
tubovesicular lipid import from the host cell surface. PLoS Pathog.
2008;4(8), e1000118.
20. Hu G, Cabrera A, Kono M, Mok S, Chaal BK, Haase S, et al. Transcriptional
profiling of growth perturbations of the human malaria parasite
Plasmodium falciparum. Nat Biotechnol. 2010;28(1):91–8.
21. Scheer M, Grote A, Chang A, Schomburg I, Munaretto C, Rother M, et al.
BRENDA, the enzyme information system in 2011. Nucleic Acids Res.
2011;39(Database issue):D670–6.
22. Iorio F, Tagliaferri R, di Bernardo D. Identifying network of drug mode of
action by gene expression profiling. J Comput Biol. 2009;16(2):241–51.
23. Iskar M, Campillos M, Kuhn M, Jensen LJ, van Noort V, Bork P. Drug-induced
regulation of target expression. PLoS Comput Biol. 2010;6(9):10.1371/
journal.pcbi.1000925.
24. Blower PE, Yang C, Fligner MA, Verducci JS, Yu L, Richman S, et al.
Pharmacogenomic analysis: correlating molecular substructure classes with
microarray gene expression data. Pharmacogenomics J. 2002;2(4):259–71.
25. Huang Y, Blower PE, Yang C, Barbacioru C, Dai Z, Zhang Y, et al. Correlating
gene expression with chemical scaffolds of cytotoxic agents: ellipticines as
substrates and inhibitors of MDR1. Pharmacogenomics J. 2005;5(2):112–25.
26. Kitagawa E, Momose Y, Iwahashi H. Correlation of the structures of
agricultural fungicides to gene expression in Saccharomyces cerevisiae
upon exposure to toxic doses. Environ Sci Technol. 2003;37(12):2788–93.
27. Khan SA, Faisal A, Mpindi JP, Parkkinen JA, Kalliokoski T, Poso A, Kallioniemi
OP, Wennerberg K, Kaski S. Comprehensive data-driven analysis of the
impact of chemoinformatic structure on the genome-wide biological
response profiles of cancer cells to 1159 drugs. BMC Bioinformatics.
2012;13:112-2105-13-112.
28. Hall M, Frank E, Holmes G, Pfahringer B, Reutemann P, Witten I. H: The
WEKA Data Mining Software: An Update. SIGKDD Explorations.
2009;11(1):10–8.
29. Holte RC. Very simple classification rules perform well on most commonly
used datasets. Machine Learning. 1993;11:63–91.
30. Cheng T, Wang Y, Bryant SH. Investigating the correlations among the
chemical structures, bioactivity profiles and molecular targets of small
molecules. Bioinformatics. 2010;26(22):2881–8.
31. Berger SI, Iyengar R. Role of systems pharmacology in understanding drug
adverse events. Wiley Interdiscip Rev Syst Biol Med. 2011;3(2):129–35.
32. Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, Shoichet BK.
Relating protein pharmacology by ligand chemistry. Nat Biotechnol.
2007;25(2):197–206.
33. Petrelli A, Giordano S. From single- to multi-target drugs in cancer therapy:
when aspecificity becomes an advantage. Curr Med Chem. 2008;15(5):422–32.
34. Tatonetti NP, Liu T, Altman RB. Predicting drug side-effects by chemical
systems biology. Genome Biol. 2009;10(9):238. -2009-10-9-238.
Epub 2009 Sep 2.
Siwo et al. BMC Genomics  (2015) 16:1030 Page 15 of 17
35. Skulachev VP. Programmed death in yeast as adaptation? FEBS Lett.
2002;528(1–3):23–6.
36. Carmona-Gutierrez D, Eisenberg T, Buttner S, Meisinger C, Kroemer G,
Madeo F. Apoptosis in yeast: triggers, pathways, subroutines. Cell Death
Differ. 2010;17(5):763–73.
37. Gero AM, Brown GV, O'Sullivan WJ. Pyrimidine de novo synthesis during the
life cycle of the intraerythrocytic stage of Plasmodium falciparum.
J Parasitol. 1984;70(4):536–41.
38. Krungkrai SR, Aoki S, Palacpac NM, Sato D, Mitamura T, Krungkrai J, et al.
Human malaria parasite orotate phosphoribosyltransferase: functional
expression, characterization of kinetic reaction mechanism and inhibition
profile. Mol Biochem Parasitol. 2004;134(2):245–55.
39. O'Neill PM, Barton VE, Ward SA. The molecular mechanism of action of
artemisinin–the debate continues. Molecules. 2010;15(3):1705–21.
40. Jambou R, Legrand E, Niang M, Khim N, Lim P, Volney B, et al. Resistance of
Plasmodium falciparum field isolates to in-vitro artemether and point
mutations of the SERCA-type PfATPase6. Lancet. 2005;366(9501):1960–3.
41. Eckstein-Ludwig U, Webb RJ, Van Goethem ID, East JM, Lee AG, Kimura M,
et al. Artemisinins target the SERCA of Plasmodium falciparum. Nature.
2003;424(6951):957–61.
42. Krishna S, Pulcini S, Fatih F, Staines H. Artemisinins and the biological basis
for the PfATP6/SERCA hypothesis. Trends Parasitol. 2010;26(11):517–23.
43. Shandilya A, Chacko S, Jayaram B, Ghosh I. A plausible mechanism for the
antimalarial activity of artemisinin: A computational approach. Sci Rep.
2013;3:2513.
44. Bhisutthibhan J, Pan XQ, Hossler PA, Walker DJ, Yowell CA, Carlton J, et al.
The Plasmodium falciparum translationally controlled tumor protein
homolog and its reaction with the antimalarial drug artemisinin. J Biol
Chem. 1998;273(26):16192–8.
45. Bhisutthibhan J, Philbert MA, Fujioka H, Aikawa M, Meshnick SR. The
Plasmodium falciparum translationally controlled tumor protein: subcellular
localization and calcium binding. Eur J Cell Biol. 1999;78(9):665–70.
46. Chae J, Choi I, Kim C. Homology modeling and molecular docking study of
translationally controlled tumor protein and artemisinin. Arch Pharm Res.
2006;29(1):50–8.
47. Afonso A, Hunt P, Cheesman S, Alves AC. Cunha CV, do Rosario V, Cravo P:
Malaria parasites can develop stable resistance to artemisinin but lack
mutations in candidate genes atp6 (encoding the sarcoplasmic and
endoplasmic reticulum Ca2+ ATPase), tctp, mdr1, and cg10. Antimicrob
Agents Chemother. 2006;50(2):480–9.
48. Eichhorn T, Winter D, Buchele B, Dirdjaja N, Frank M, Lehmann WD, et al.
Molecular interaction of artemisinin with translationally controlled tumor
protein (TCTP) of Plasmodium falciparum. Biochem Pharmacol.
2013;85(1):38–45.
49. Mok S, Ashley EA, Ferreira PE, Zhu L, Lin Z, Yeo T, et al. Drug resistance.
Population transcriptomics of human malaria parasites reveals the
mechanism of artemisinin resistance. Science. 2015;347(6220):431–5.
50. Tucker MS, Mutka T, Sparks K, Patel J, Kyle DE. Phenotypic and genotypic
analysis of in vitro-selected artemisinin-resistant progeny of Plasmodium
falciparum. Antimicrob Agents Chemother. 2012;56(1):302–14.
51. Klonis N, Xie SC, McCaw JM, Crespo-Ortiz MP, Zaloumis SG, Simpson JA, et
al. Altered temporal response of malaria parasites determines differential
sensitivity to artemisinin. Proc Natl Acad Sci U S A. 2013;110(13):5157–62.
52. Witkowski B, Lelievre J, Barragan MJ, Laurent V, Su XZ, Berry A, et al.
Increased tolerance to artemisinin in Plasmodium falciparum is mediated by
a quiescence mechanism. Antimicrob Agents Chemother. 2010;54(5):1872–7.
53. Bommer UA, Heng C, Perrin A, Dash P, Lobov S, Elia A, et al. Roles of the
translationally controlled tumour protein (TCTP) and the double-stranded
RNA-dependent protein kinase, PKR, in cellular stress responses. Oncogene.
2010;29(5):763–73.
54. Bommer UA, Thiele BJ. The translationally controlled tumour protein (TCTP).
Int J Biochem Cell Biol. 2004;36(3):379–85.
55. Gachet Y, Tournier S, Lee M, Lazaris-Karatzas A, Poulton T, Bommer UA: The
growth-related, translationally controlled protein P23 has properties of a
tubulin binding protein and associates transiently with microtubules during
the cell cycle. J Cell Sci. 1999;112(Pt 8)(Pt 8):1257–1271.
56. Klonis N, Crespo-Ortiz MP, Bottova I, Abu-Bakar N, Kenny S, Rosenthal PJ,
et al. Artemisinin activity against Plasmodium falciparum requires hemoglobin
uptake and digestion. Proc Natl Acad Sci U S A. 2011;108(28):11405–10.
57. Sibmooh N, Pipitaporn B, Wilairatana P, Dangdoungjai J, Udomsangpetch R,
Looareesuiwan S, et al. Effect of artemisinin on lipid peroxidation and
fluidity of the erythrocyte membrane in malaria. Biol Pharm Bull.
2000;23(11):1275–80.
58. Berman PA, Adams PA. Artemisinin enhances heme-catalysed oxidation of
lipid membranes. Free Radic Biol Med. 1997;22(7):1283–8.
59. Chen N, LaCrue AN, Teuscher F, Waters NC, Gatton ML, Kyle DE, et al. Fatty
Acid Synthesis and Pyruvate Metabolism Pathways Remain Active in
Dihydroartemisinin-Induced Dormant Ring Stages of Plasmodium
falciparum. Antimicrob Agents Chemother. 2014;58(8):4773–81.
60. McNamara C, Winzeler EA. Target identification and validation of novel
antimalarials. Future Microbiol. 2011;6(6):693–704.
61. Bozdech Z, Llinas M, Pulliam BL, Wong ED, Zhu J, DeRisi JL. The
transcriptome of the intraerythrocytic developmental cycle of Plasmodium
falciparum. PLoS Biol. 2003;1(1), E5.
62. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al.
Exploration, normalization, and summaries of high density oligonucleotide
array probe level data. Biostatistics. 2003;4(2):249–64.
63. Clark TA, Schweitzer AC, Chen TX, Staples MK, Lu G, Wang H, et al.
Discovery of tissue-specific exons using comprehensive human exon
microarrays. Genome Biol. 2007;8(4):R64.
64. Bolton E, Wang Y, Thiessen PA, Bryant SH, et al. PubChem: Integrated
Platform of Small Molecules and Biological Activities. In: Annual Reports in
Computational Chemistry. Vol 4. Washington, DC: American Chemical
Society; 2008. Chapter 12.
65. PubChem [ftp://ftp.ncbi.nlm.nih.gov/pubchem/specifications/
pubchem_fingerprints.txt]
66. Cao Y, Charisi A, Cheng LC, Jiang T, Girke T. ChemmineR: a compound
mining framework for R. Bioinformatics. 2008;24(15):1733–4.
67. Venables WN, Ripley BD. Modern Applied Statistics with S: 4th ed. New York:
Springer; 2002.
68. Law PJ, Claudel-Renard C, Joubert F, Louw AI, Berger DK. MADIBA: a web
server toolkit for biological interpretation of Plasmodium and plant gene
clusters. BMC Genomics 2008;9:105-2164-9-105.
69. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al.
Cytoscape: a software environment for integrated models of biomolecular
interaction networks. Genome Res. 2003;13(11):2498–504.
70. Ferdig MT, Cooper RA, Mu J, Deng B, Joy DA, Su XZ, et al. Dissecting the
loci of low-level quinine resistance in malaria parasites. Mol Microbiol.
2004;52(4):985–97.
71. Sen S, Churchill GA. A statistical framework for quantitative trait mapping.
Genetics. 2001;159(1):371–87.
72. Painter HJ, Morrisey JM, Mather MW, Vaidya AB. Specific role of
mitochondrial electron transport in blood-stage Plasmodium falciparum.
Nature. 2007;446(7131):88–91.
73. Gopalakrishnan AM, Kumar N. Opposing roles for two molecular forms of
replication protein A in Rad51-Rad54-mediated DNA recombination in
Plasmodium falciparum. MBio. 2013;4(3):e00252–13.
74. Uhlemann AC, Cameron A, Eckstein-Ludwig U, Fischbarg J, Iserovich P,
Zuniga FA, et al. A single amino acid residue can determine the sensitivity
of SERCAs to artemisinins. Nat Struct Mol Biol. 2005;12(7):628–9.
75. Dahl EL, Shock JL, Shenai BR, Gut J, DeRisi JL, Rosenthal PJ. Tetracyclines
specifically target the apicoplast of the malaria parasite Plasmodium
falciparum. Antimicrob Agents Chemother. 2006;50(9):3124–31.
76. Korsinczky M, Chen N, Kotecka B, Saul A, Rieckmann K, Cheng Q. Mutations
in Plasmodium falciparum cytochrome b that are associated with
atovaquone resistance are located at a putative drug-binding site.
Antimicrob Agents Chemother. 2000;44(8):2100–8.
77. Surolia N, Padmanaban G. Chloroquine inhibits heme-dependent protein
synthesis in Plasmodium falciparum. Proc Natl Acad Sci U S A.
1991;88(11):4786–90.
78. Slater AF, Cerami A. Inhibition by chloroquine of a novel haem polymerase
enzyme activity in malaria trophozoites. Nature. 1992;355(6356):167–9.
79. Mungthin M, Bray PG, Ridley RG, Ward SA. Central role of hemoglobin
degradation in mechanisms of action of 4-aminoquinolines, quinoline
methanols, and phenanthrene methanols. Antimicrob Agents Chemother.
1998;42(11):2973–7.
80. Budimulja AS. Syafruddin, Tapchaisri P, Wilairat P, Marzuki S: The sensitivity
of Plasmodium protein synthesis to prokaryotic ribosomal inhibitors. Mol
Biochem Parasitol. 1997;84(1):137–41.
81. Imwong M, Russell B, Suwanarusk R, Nzila A, Leimanis ML, Sriprawat K, et al.
Methotrexate is highly potent against pyrimethamine-resistant Plasmodium
vivax. J Infect Dis. 2011;203(2):207–10.
Siwo et al. BMC Genomics  (2015) 16:1030 Page 16 of 17
82. Rastelli G, Pacchioni S, Sirawaraporn W, Sirawaraporn R, Parenti MD, Ferrari
AM. Docking and database screening reveal new classes of Plasmodium
falciparum dihydrofolate reductase inhibitors. J Med Chem.
2003;46(14):2834–45.
83. Kumar R, Musiyenko A, Barik S. The heat shock protein 90 of Plasmodium
falciparum and antimalarial activity of its inhibitor, geldanamycin. Malar J.
2003;2:30.
84. Monaghan P, Bell A. A Plasmodium falciparum FK506-binding protein (FKBP)
with peptidyl-prolyl cis-trans isomerase and chaperone activities. Mol
Biochem Parasitol. 2005;139(2):185–95.
85. Bailly E, Jambou R, Savel J, Jaureguiberry G. Plasmodium falciparum:
differential sensitivity in vitro to E-64 (cysteine protease inhibitor) and
Pepstatin A (aspartyl protease inhibitor). J Protozool. 1992;39(5):593–9.
86. Andrews KT, Fairlie DP, Madala PK, Ray J, Wyatt DM, Hilton PM, et al.
Potencies of human immunodeficiency virus protease inhibitors in vitro
against Plasmodium falciparum and in vivo against murine malaria.
Antimicrob Agents Chemother. 2006;50(2):639–48.
87. Czesny B, Goshu S, Cook JL, Williamson KC. The proteasome inhibitor
epoxomicin has potent Plasmodium falciparum gametocytocidal activity.
Antimicrob Agents Chemother. 2009;53(10):4080–5.
88. Prasad R. Atul, Kolla VK, Legac J, Singhal N, Navale R, Rosenthal PJ, Sijwali PS:
Blocking Plasmodium falciparum development via dual inhibition of
hemoglobin degradation and the ubiquitin proteasome system by MG132.
PLoS One. 2013;8(9), e73530.
89. Surolia N, Surolia A. Triclosan offers protection against blood stages of
malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum. Nat
Med. 2001;7(2):167–73.
90. Labaied M, Dagan A, Dellinger M, Geze M, Egee S, Thomas SL, et al. Anti-
Plasmodium activity of ceramide analogs. Malar J. 2004;3:49.
91. Ch'ng JH, Kotturi SR, Chong AG, Lear MJ, Tan KS. A programmed cell death
pathway in the malaria parasite Plasmodium falciparum has general features
of mammalian apoptosis but is mediated by clan CA cysteine proteases.
Cell Death Dis. 2010;1, e26.
92. Chaal BK, Gupta AP, Wastuwidyaningtyas BD, Luah YH, Bozdech Z. Histone
deacetylases play a major role in the transcriptional regulation of the
Plasmodium falciparum life cycle. PLoS Pathog. 2010;6(1), e1000737.
93. Ono T, Cabrita-Santos L, Leitao R, Bettiol E, Purcell LA, Diaz-Pulido O, et al.
Adenylyl cyclase alpha and cAMP signaling mediate Plasmodium sporozoite
apical regulated exocytosis and hepatocyte infection. PLoS Pathog.
2008;4(2), e1000008.
94. Umeda T, Tanaka N, Kusakabe Y, Nakanishi M, Kitade Y, Nakamura KT.
Molecular basis of fosmidomycin's action on the human malaria parasite
Plasmodium falciparum. Sci Rep. 2011;1:9.
95. Iwanaga T, Sugi T, Kobayashi K, Takemae H, Gong H, Ishiwa A, et al.
Characterization of Plasmodium falciparum cdc2-related kinase and the
effects of a CDK inhibitor on the parasites in erythrocytic schizogony.
Parasitol Int. 2013;62(5):423–30.
96. Manhani KK, Arcuri HA, da Silveira NJ, Uchoa HB, de Azevedo WF, Jr CF.
Molecular models of protein kinase 6 from Plasmodium falciparum. J Mol
Model. 2005;12(1):42–8.
97. Wong RP, Davis TM. In vitro antimalarial activity and drug interactions of
fenofibric acid. Antimicrob Agents Chemother. 2012;56(6):2814–8.
98. Usanga EA, O'Brien E, Luzzato L. Mitotic inhibitors arrest the growth of
Plasmodium falciparum. FEBS Lett. 1986;209(1):23–7.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Siwo et al. BMC Genomics  (2015) 16:1030 Page 17 of 17
